VAXELIS (Maxx Pharma Pty Ltd)
Product name
VAXELIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
158 (255 working days)
Active ingredients
DTPa5-HB-IPV-Hib
Registration type
NCE/NBE
Indication
VAXELIS (DTPa5-HB-IPV-Hib) (suspension for injection) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).
The use of VAXELIS should be in accordance with official recommendations.